Pharmacogenetics of depression in elderly patients;Pharmacogénétique de la dépression du sujet âgé

Psychologie et NeuroPsychiatrie du Vieillissement

Volumn 7, Issue 1, 2009, Pages 43-55

  Monnin, Julie ^a   Haffen, Emmanuel ^a   Sechter, Daniel ^a   Vandel, Pierre ^a  

^a HÔPITAL SAINT JACQUES   (France)

Author keywords

CYP2D6; Depression; Elderly; Pharmacogenetics; Serotonin transporter

Indexed keywords

AMITRIPTYLINE; CIMETIDINE; CITALOPRAM; CYTOCHROME P450 2D6; DILTIAZEM; DIPHENHYDRAMINE; FLUVOXAMINE; MIRTAZAPINE; NORTRIPTYLINE; ORPHENADRINE; PAROXETINE; QUINIDINE; SEROTONIN TRANSPORTER; SERTRALINE; VENLAFAXINE;

ADVERSE OUTCOME; CLINICAL EVALUATION; CLINICAL PRACTICE; DEPRESSION; DIET; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG METABOLISM; DRUG MONITORING; DRUG WITHDRAWAL; GENE; GENE IDENTIFICATION; GENETIC POLYMORPHISM; GROUPS BY AGE; HUMAN; HUMAN GENOME; PHARMACOGENETICS; PHYSICIAN; PREDICTION; RECURRENT DISEASE; REVIEW; TREATMENT INDICATION; TREATMENT RESPONSE;

AGED; ANTIDEPRESSIVE AGENTS; CYTOCHROME P-450 CYP2D6; DEPRESSIVE DISORDER; HUMANS; PHARMACOGENETICS; SEROTONIN;

EID: 65349169456     PISSN: 17601703     EISSN: 19506988     Source Type: Journal    
DOI: 10.3684/pnv.2009.0157     Document Type: Review

References (89)

1. Lopez AD. The evolution of the Global Burden of Disease framework for disease, injury and risk factor quantification : developing the evidence base for national, regional and global public health action. Global Health 2005 ; 1 : 5.
2. Lopez AD, Murray CC. The global burden of disease, 1990-2020. Nat Med 1998; 4: 1241-3.
3. Murray CJ, Lopez AD. Evidence-based health policy--lessons from the Global Burden of Disease Study. Science 1996; 274: 740-3.
4. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 2006 ; 3 : e442.
5. Kessler RC, Angermeyer M, Anthony JC, De Graaf R, Demytte- naere K, Gasquet I, et al. Lifetime prevalence and age-of-onset distributions of mental disorders in the World Health Organization's World Mental Health Survey Initiative. World Psychiatry 2007 ; 6 : 168-76.
6. Kessler RC, McGonagle KA, Zhao S, Nelson CB, Hughes M, Eshleman S, et al. Lifetime and 12-month prevalence of DSM- III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psychiatry 1994; 51 :8-19.
7. Lekman M, Paddock S, McMahon FJ. Pharmacogenetics of major depression : insights from level 1 of the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial. Mol Diagn Ther 2008 ; 12 : 321-30.
8. Binder EB, Holsboer F. Pharmacogenomics and antidepressant drugs. Ann Med 2006 ; 38 : 82-94.
9. Kirchheiner J, Bertilsson L, Bruus H, Wolff A, Roots I, Bauer M. Individualized medicine - implementation of pharmacogenetic diagnostics in antidepressant drug treatment of major depressive disorders. Pharmacopsychiatry 2003 ; 36(Suppl. 3) : S235-43.
10. Lotrich FE, Pollock BG. Aging and clinical pharmacology: implications for antidepressants. J Clin Pharmacol 2005 ; 45 :1106-22.
11. Nebert DW, Jorge-Nebert L, Vesell ES. Pharmacogenomics and "individualized drug therapy": high expectations and disappointing achievements. Am J Pharmacogenomics 2003; 3: 361-70.
12. Sjöqvist F, Eliasson E. The convergence of conventional therapeutic drug monitoring and pharmacogenetic testing in personalized medicine : focus on antidepressants. Clin Pharmacol Ther 2007 ; 81 : 899-902.
13. Brodie BB. On mice, microsomes and man. Pharmacologist 1964 ; 6 : 12-26.
14. Dahl ML, Sjöqvist F. Pharmacogenetic method as a complement to therapeutic monitoring of antidepressants and neuroleptics. Drug Monitoring 2000 ; 22 : 114-7.
15. Tsapakis EM, Basu A, Aitchison KJ. Clinical relevance of discoveries in psychopharmacogenetics. Advances in Psychiatric Treatment 2004; 10 : 455-65.
16. Carson PE, Flanagan CL, Ickes CE, Alvong AS. Enzymatic deficiency in primaquine sensitive erythrocytes. Science 1956; 124: 484-5.
17. Kalow W. Familial incidence of low pseudocholinesterase level. Lancet 1956; II : 576-7.
18. Meisel C, Gerloff T, Kirchheiner J, Mrozikiewicz PM, Niewinski P, Brockmoller J, et al. Implications of pharmacogenetics for individualizing drug treatment and for study design. J Mol Med 2003 ;81 : 154-67.
19. Mahgoub A, Idle JR, Dring LG, Lancaster R, Smith RL. Polymorphic hydroxylation of debrisoquine in man. Lancet 1977 ; II :584-6.
20. Eichelbaum M, Spannbrücker N, Steincke B, Dengler HJ. Defective-N-oxidation of sparteine in man : a new pharmacogenetic defect. Eur J Clin Pharmacol 1979 ; 16 : 183-7.
21. Gonzalez FJ. The molecular biology of cytochrome P450s. Pharmacol Rev 1988 ; 40 : 243-88.
22. Gonzalez FJ, Skoda RC, Kimura S, Umeno M, Zanger UM, Nebert DW, et al. Characterization of the common genetic defect in humans deficient in debrisoquine metabolism. Nature 1988;331 : 442-6.
23. Malhotra AK, Murphy Jr. GM, Kennedy JL. Pharmacogenetics of psychotropic drug response. Am J Psychiatry 2004; 161:780-96.
24. Coutts RT, Urichuk LJ. Polymorphic cytochromes P450 and drugs used in psychiatry. CellMolNeurobiol1999; 19: 325-54.
25. Vandel P. Antidepressant drugs in the elderly-role of the cytochrome P450 2D6. World J Biol Psychiatry 2003 ; 4 : 74-80.
26. Egger T, Dormann H, Ahne G, Pahl A, Runge U, Azaz-Livshits T, et al. Cytochrome p450 polymorphisms in geriatric patients : impact on adverse drug reactions-- a pilot study. Drugs Aging 2005 ; 22 : 265-72.
27. Shah RR. Drug development and use in the elderly : search for the right dose and dosing regimen (Parts I and II). Br J Clin Pharmacol 2004 ; 58 : 452-69.
28. Parikh C. Antidepressants in the elderly: challenges for study design and their interpretation. Br J Clin Pharmacol 2000; 49:539-47.
29. Cherma MD, Lofgren UB, Almkvist G, Hallert C, Bengtsson F. Assessment of the prescription of antidepressant drugs in elderly nursing home patients : a clinical and laboratory follow-up investigation. J Clin Psychopharmacol 2008 ; 28 : 424-31.
30. Pollock BG. Adverse reactions of antidepressants in elderly patients. J Clin Psychiatry 1999 ; 60(Suppl. 20): 4-8.
31. Pollock BG, Perel JM, Paradis CF, Fasiczka AL, Reynolds 3rd CF. Metabolic and physiologic consequences of nortriptyline treatment in the elderly. Psychopharmacol Bull 1994 ; 30 : 145-50.
32. Murphy Jr. GM, Pollock BG, Kirshner MA, Pascoe N, CheukW, Mulsant BH, et al. CYP2D6 genotyping with oligonucleotide microarrays and nortriptyline concentrations in geriatric depression. Neuropsychopharmacology 2001 ; 25 : 737-43.
33. Gildengers AG, Houck PR, Mulsant BH, Pollock BG, Mazumdar S, Miller MD, et al. Course and rate of antidepressant response in the very old. J Affect Disord 2002 ; 69 : 177-84.
34. Buffum MD, Buffum JC. Treating depression in the elderly : an update on antidepressants. Geriatr Nurs 2005; 26: 138-42.
35. Dasgupta K. Treatment of depression in elderly patients : recent advances. Arch Fam Med 1998 ; 7 : 274-80.
36. Roose SP, Schatzberg AF. The efficacy of antidepressants in the treatment of late-life depression. J Clin Psychopharmacol 2005 ; 25 : S1-7.
37. Alexanderson B, Evans DA, Sjoqvist F. Steady-state plasma levels of nortriptyline in twins : influence of genetic factors and drug therapy. Br Med J 1969 ; 4 : 764-8.
38. Hammer W, Sjcöqvist F. Plasma levels of monomethylated tricyclic antidepressants during treatment with imipramine-like compounds. Life Sci 1967 ; 6 : 1895-903.
39. Vandel P, Talon JM, Haffen E, Sechter D. Pharmacogenetics and drug therapy in psychiatry--the role of the CYP2D6 polymorphism. Curr Pharm Des 2007 ; 13 : 241-50.
40. Kirchheiner J, Brosen K, Dahl ML, Gram LF, Kasper S, Roots I, et al. CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants : a first step towards subpopulation- specific dosages. Acta Psychiatr Scand 2001 ; 104 : 173-92.
41. Ingelman-Sundberg M. Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6) : clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J 2005; 5:6-13.
42. Abraham BK, Adithan C, Mohanasundaram J, Shashindran CH, Koumaravelou K, Asad M. Genetic polymorphism of CYP2D6 in Tamil population. Eur J Clin Pharmacol 2001 ; 56: 849-50.
43. Marez D, Legrand M, Sabbagh N, Guidice JM, Spire C, Lafitte JJ, et al. Polymorphism of the cytochrome P450 CYP2D6 gene in a European population : characterization of 48 mutations and 53 alleles, their frequencies and evolution. Pharmacogenetics 1997 ;7 : 193-202.
44. Sachse C, Brockmoller J, Bauer S, Roots I. Cytochrome P450 2D6 variants in a Caucasian population : allele frequencies and phenotypic consequences. Am J Hum Genet 1997 ; 60 : 284-95.
45. Schaeffeler E, Schwab M, Eichelbaum M, Zanger UM. CYP2D6 genotyping strategy based on gene copy number determination by TaqMan real-time PCR. Hum Mutat 2003 ; 22 : 476-85.
46. Gaedigk A, Blum M, Gaedigk R, Eichelbaum M, Meyer UA. Deletion of the entire cytochrome P450 CYP2D6 gene as a cause of impaired drug metabolism in poor metabolizers of the debriso- quine/sparteine polymorphism. Am J Hum Genet 1991; 48:943-50.
47. Raimundo S, Fischer J, Eichelbaum M, Griese EU, Schwab M, Zanger UM. Elucidation of the genetic basis of the common 'intermediate metabolizer' phenotype for drug oxidation by CYP2D6. Pharmacogenetics 2000 ; 10 : 577-81.
48. Gaedigk A, Ndjountche L, Divakaran K, Dianne Bradford L, Zineh I, Oberlander TF, et al. Cytochrome P4502D6 (CYP2D6) gene locus heterogeneity: characterization of gene duplication events. Clin Pharmacol Ther 2007 ; 81 : 242-51.
49. Ingelman-Sundberg M, Sim SC, Gomez A, Rodriguez-Antona C. Influence of cytochrome P450 polymorphisms on drug therapies : pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol Ther 2007 ; 116 : 496-526.
50. Dalen P, Dahl ML, Ruiz ML, Nordin C, Bertilsson L. 10- hydroxylation of nortriptyline in white persons with 0, 1, 2, 3, and 13 functional CYP2D6 genes. Clin Pharamcol Ther 1998 ; 63 :444-52.
51. Bertilsson L, Dahl ML, Dalen P, Al-Shurbaji A. Molecular genetics of CYP2D6 : clinical relevance with focus on psychotropic drugs. Br J Clin Pharmacol 2002 ; 53 : 111-22.
52. Shams ME, Arneth B, Hiemke C, Dragicevic A, Muller MJ, Kaiser R, et al. CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine. J Clin Pharm Ther 2006; 31 : 493-502.
53. Steimer W, Zopf K, von Amelunxen S, Pfeiffer H, Bachofer J, Popp J, et al. Amitriptyline or not, that is the question : pharmaco- genetic testing of CYP2D6 and CYP2C19 identifies patients with low or high risk for side effects in amitriptyline therapy. Clin Chem 2005 ; 51 : 376-85.
54. de Leon J, Armstrong SC, Cozza KL. Clinical guidelines for psychiatrists for the use of pharmacogenetic testing for CYP450 2D6 and CYP450 2C19. Psychosomatics 2006 ; 47 : 75-85.
55. Kirchheiner J, Seeringer A. Clinical implications of pharmaco- genetics of cytochrome P450 drug metabolizing enzymes. Bio- chim Biophys Acta 2007 ; 1770 : 489-94.
56. Pollock BG, Perel JM, Altieri LP, Kirshner M, Fasiczka AL, Houck PR, et al. Debrisoquine hydroxylation phenotyping in geriatric psychopharmacology. Psychopharmacol Bull 1992 ; 28 : 163-8.
57. Bottorff MB, Lalonde RL, Kazierad DJ, Hoon TJ, Tsiu SJ, Mir- vis DM. The effects of encainide versus diltiazem on the oxidative metabolic pathways of antipyrine. Pharmacotherapy 1989; 9:315-21.
58. Derenne F, Joanne C, Vandel S, Bertschy G, Volmat R, Bechtel P. Debrisoquine oxidative phenotyping and psychiatric drug treatment. Eur J Clin Pharmacol 1989 ; 36 : 53-8.
59. Gram LF, Debruyne D, Caillard V, Boulenger JP, Lacotte J, Moulin M, et al. Substantial rise in sparteine metabolic ratio during haloperidol treatment. Br J Clin Pharmacol 1989; 27:272-5.
60. Philip PA, James CA, Rogers HJ. The influence of cimetidine on debrisoquine 4-hydroxylation in extensive metabolizers. Eur J Clin Pharmacol 1989 ; 36 : 319-21.
61. Poirier J, Roy M, Campanella G, Cloutier T, Paris S. Debrisoquine metabolism in parkinsonian patients treated with antihista- mine drugs. Lancet 1987 ; 2 : 386.
62. Speirs CJ, Murray S, Boobis AR, Seddon CE, Davies DS. Quinidine and the identification of drugs whose elimination is impaired in subjects classified as poor metabolizers of debrisoquine. Br J Clin Pharmacol 1986 ; 22 : 739-43.
63. Yamada H, Dahl ML, Lannfelt L, Viitanen M, Winblad B, Sjoq- vist F. CYP2D6 and CYP2C19 genotypes in an elderly Swedish population. Eur J Clin Pharmacol 1998; 54: 479-81.
64. Kim H, Lim SW, Kim S, Kim JW, Chang YH, Carroll BJ, et al. Monoamine transporter gene polymorphisms and antidepressant response in Koreans with late-life depression. JAMA 2006 ; 296 :1609-18.
65. Murphy Jr. GM, Hollander SB, Rodrigues HE, Kremer C, Schatzberg AF. Effects of the serotonin transporter gene promoter polymorphism on mirtazapine and paroxetine efficacy and adverse events in geriatric major depression. Arch Gen Psychiatry 2004 ; 61 : 1163-9.
66. Murphy Jr. GM, Kremer C, Rodrigues HE, Schatzberg AF. Pharmacogenetics of antidepressant medication intolerance. Am J Psychiatry 2003 ; 160 : 1830-5.
67. Dahl ML, Bertilsson L, Nordin C. Steady-state plasma levels of nortriptyline and its 10-hydroxy metabolite : relationship to the CYP2D6 genotype. Psychopharmacology 1996 ; 123 : 315-9.
68. Morita S, Shimoda K, Someya T, Yoshimura Y, Kamijima K, Kato N. Steady-state plasma levels of nortriptyline and its hydro-xylated metabolites in Japanese patients : impact of CYP2D6 genotype on the hydroxylation of nortriptyline. J Clin Psychophar- macol 2000; 20: 141-9.
69. Yue QY, Zhong ZH, Tybring G, Dalen P, Dahl ML, Bertilsson L, et al. Pharmacokinetics of nortriptyline and its 10-hydroxy metabolite in Chinese subjects of different CYP2D6 genotypes. Clin Pharmacol Ther 1998 ; 64 : 385-90.
70. Lesch KP, Bengel D, Heils A, Sabol SZ, Greenberg BD, Petri S, et al. Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science 1996;274 : 1527-31.
71. Greenberg BD, Tolliver TJ, Huang SJ, Li Q, Bengel D, Murphy DL. Genetic variation in the serotonin transporter promoter region affects serotonin uptake in human blood platelets. Am J Med Genet 1999 ; 88 : 83-7.
72. Heils A, Teufel A, Petri S, Stober G, Riederer P, Bengel D, et al. Allelic variation of human serotonin transporter gene expression. J Neurochem 1996 ; 66 : 2621-4.
73. Heinz A, Jones DW, Mazzanti C, Goldman D, Ragan P, Hommer D, et al. A relationship between serotonin transporter genotype and in vivo protein expression and alcohol neurotoxicity. Biol Psychiatry 2000 ; 47 : 643-9.
74. Zanardi R, Benedetti F, Di Bella D, Catalano M, Smeraldi E. Efficacy of paroxetine in depression is influenced by a functional polymorphism within the promoter of the serotonin transporter gene. J Clin Psychopharmacol 2000 ; 20 : 105-7.
75. Smeraldi E, Zanardi R, Benedetti F, Di Bella D, Perez J, Cata- lano M. Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine. Mol Psychiatry 1998 ; 3 : 508-11.
76. Serretti A, Cusin C, Rausch JL, Bondy B, Smeraldi E. Pooling pharmacogenetic studies on the serotonin transporter : a mega-analysis. Psychiatry Res 2006 ; 145 : 61-5.
77. Perlis RH, Mischoulon D, Smoller JW, Wan YJ, Lamon-Fava S, Lin KM, et al. Serotonin transporter polymorphisms and adverse effects with fluoxetine treatment. Biol Psychiatry 2003; 54:879-83.
78. Dogan O, Yuksel N, Ergun MA, Yilmaz A, Ilhan MN, Karslioglu HE, et al. Serotonin transporter gene polymorphisms and sertra- line response in major depression patients. Genet Test 2008 ; 12 :225-31.
79. Kraft JB, Peters EJ, Slager SL, Jenkins GD, Reinalda MS, McGrath PJ, et al. Analysis of association between the serotonin transporter and antidepressant response in a large clinical sample. Biol Psychiatry 2007 ; 61 : 734-42.
80. Minov C, Baghai TC, Schule C, Zwanzger P, Schwarz MJ, Zill P, et al. Serotonin-2A-receptor and -transporter polymorphisms : lack of association in patients with major depression. Neurosci Lett 2001 ; 303 : 119-22.
81. Yoshida K, Ito K, Sato K, Takahashi H, Kamata M, Higuchi H, et al. Influence of the serotonin transporter gene-linked polymorphic region on the antidepressant response to fluvoxamine in Japanese depressed patients. Prog Neuropsychopharmacol Biol Psychiatry 2002 ; 26 : 383-6.
82. Yu YW, Tsai SJ, Chen TJ, Lin CH, Hong CJ. Association study of the serotonin transporter promoter polymorphism and symptomatology and antidepressant response in major depressive disorders. Mol Psychiatry 2002 ; 7 : 1115-9.
83. Pollock BG, Ferrell RE, Mulsant BH, Mazumdar S, Miller M, Sweet RA, et al. Allelic variation in the serotonin transporter promoter affects onset of paroxetine treatment response in late-life depression. Neuropsychopharmacology 2000 ; 23 : 587-90.
84. Wong ML, Whelan F, Deloukas P, Whittaker P, Delgado M, Cantor RM, et al. Phosphodiesterase genes are associated with susceptibility to major depression and antidepressant treatment response. Proc Natl Acad Sci USA 2006 ; 103 : 15124-9.
85. Perlis RH, Purcell S, Fava M, Fagerness J, Rush AJ, Trivedi MH, et al. Association between treatment-emergent suicidal ideation with citalopram and polymorphisms near cyclic adenosine monophosphate response element binding protein in the STAR*D study. Arch Gen Psychiatry 2007 ; 64 : 689-97.
86. Tadic A, Rujescu D, Muller MJ, Kohnen R, Stassen HH, Szegedi A, et al. Association analysis between variants of the interleukin-1beta and the interleukin-1 receptor antagonist gene and antidepressant treatment response in major depression. Neu- ropsychiatr Dis Treat 2008; 4: 269-76.
87. Szegedi A, Rujescu D, Tadic A, Muller MJ, Kohnen R, Stassen HH, et al. The catechol-O-methyltransferase Val108/158Met polymorphism affects short-term treatment response to mirtazapine, but not to paroxetine in major depression. Pharmacogenomics J 2005 ; 5 : 49-53.
88. Tsai SJ, Gau YT, Hong CJ, Liou YJ, Yu YW, Chen TJ. Sexually dimorphic effect of catechol-O-methyltransferase val158met polymorphism on clinical response to fluoxetine in major depressive patients. J Affect Disord 2009 ; 113 : 183-7.
89. Holsboer F. How can we realize the promise of personalized antidepressant medicines ? Nat Rev Neurosci 2008 ; 9 : 638-46.